VivoSeq
Other

Pelvic Organ Prolapse

15

Pipeline Programs↗

5

Active Trials↗

8

Companies Involved↗

Pelvic Organ Prolapse is an emerging landscape with 15 programs across 8 companies. The most active players are Eli Lilly, Roche, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 11 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

88/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 3Roche logo

Roche

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3A

Amring

1 program

ApprovedA

AFT Pharmaceuticals, Ltd.

1 program

ApprovedV

Viatris Specialty LLC

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

16

clinical trials

Completed7 · 44%
Unknown status3 · 19%
Not yet recruiting2 · 13%
Active, not recruiting2 · 13%
Terminated1 · 6%
Recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

A Retrospective and Long-Term Prospective Post Market Clinical Follow-up (PMCF) Study of the GYNECARE GYNEMESH® PS Nonabsorbable PROLENE® Soft Mesh
Recruiting·EEthicon, Inc.·N/A·NCT04829058·100 enrolled
Novel Vaginal Orthosis for Post-Surgical Healing After Vaginal Reconstructive Surgery For Pelvic Organ Prolapse (NOVa Study)
Active, not recruiting·UUniversity of Alabama at Birmingham·Preclinical·NCT05812859·30 enrolled
Platelet Rich Plasma as an Adjunct Therapy at the Time of Transvaginal Native Tissue Prolapse Surgery
Active, not recruiting·UUniversity of Alabama at Birmingham·Preclinical·NCT05731284·60 enrolled
Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery
Not yet recruiting·QQueen's University·Phase 3·NCT07030426·180 enrolled
Improving Uroflowmetry Interpretability: Evaluating the Impact of Patient Reminder Systems
Not yet recruiting·OOhio State University·Preclinical·NCT07692789·162 enrolled
The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse
Completed·TTriHealth Inc.·Phase 3·NCT00803335·54 enrolled
IV Acetaminophen for Postoperative Pain After Pelvic Organ Prolapse Repair
Completed·—·Phase 4·NCT02155738·204 enrolled
Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse
Completed·TTriHealth Inc.·Phase 4·NCT02449915·70 enrolled
Intraperitoneal Bupivacaine for Pelvic Organ Prolapse
Completed·IIndiana University·Phase 4·NCT06120530·91 enrolled
Alfacalcidol Supplementation on Levator Ani Muscle Strength of Menopausal Pelvic Organ Prolapse Patients
Completed·UUniversitas Padjadjaran·Phase 3·NCT05505253·48 enrolled
Preoperative Oestrogen in Postmenopausal Women With Pelvic Organ Prolapse
Completed·MMedical University of Vienna·Phase 4·NCT03779633·120 enrolled
Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients
Completed·UUniversidade Federal do Paraná·Phase 4·NCT03032848·69 enrolled
Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse
Terminated·TThe University of Texas Medical Branch, Galveston·Phase 4·NCT01886794·7 enrolled
Surgical Intervention With DermaPure vs Native Tissue in Pelvic Organ Prolapse
Unknown status·CColorado Pelvic Floor Consultants·Phase 4·NCT03939715·50 enrolled
the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery
Unknown status·PPeking University People's Hospital·Phase 3·NCT02599311·1,000 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)